Preeclampsia: novel insights from global RNA profiling of trophoblast subpopulations

American Journal of Obstetrics and Gynecology

Volumn 217, Issue 2, 2017, Pages 200.e1-200.e17

  Gormley, Matthew ^a   Ona, Katherine ^a   Kapidzic, Mirhan ^a   Garrido Gomez, Tamara ^a   Zdravkovic, Tamara ^a   Fisher, Susan J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

biomarker; cytotrophoblast; laser microdissection; mRNA; non protein coding RNA; placenta; preeclampsia; syncytiotrophoblast

Indexed keywords

LIPID; LONG UNTRANSLATED RNA; MESSENGER RNA; OXYGEN; PROGESTERONE; RNA; SMALL NUCLEOLAR RNA; TRANSFORMING GROWTH FACTOR BETA; UNTRANSLATED RNA; VASCULOTROPIN;

ADULT; ARTICLE; CLINICAL ARTICLE; COILED BODY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOTROPHOBLAST; DIASTOLIC BLOOD PRESSURE; FEMALE; GENE EXPRESSION; GENE ONTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOLOCALIZATION; IN SITU HYBRIDIZATION; LASER MICRODISSECTION; MATERNAL AGE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PLACENTA; PREECLAMPSIA; PRIORITY JOURNAL; PROTEINURIA; RNA ISOLATION; RNA STRUCTURE; SYNCYTIOTROPHOBLAST; SYSTOLIC BLOOD PRESSURE; TROPHOBLAST; CASE CONTROL STUDY; GENETICS; PATHOLOGY; PREGNANCY;

ADULT; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; RNA, LONG NONCODING; TROPHOBLASTS;

EID: 85018425988     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2017.03.017     Document Type: Article

References (119)

1. Burton, G.J., Jauniaux, E., What is the placenta?. Am J Obstet Gynecol 213:suppl (2015), S6.e1–S6.e8.
2. Brosens, I., Pijnenborg, R., Vercruysse, L., Romero, R., The “Great Obstetrical Syndromes” are associated with disorders of deep placentation. Am J Obstet Gynecol 204 (2011), 193–201.
3. Labarrere, C.A., DiCarlo, H.L., Bammerlin, E., et al. Failure of physiologic transformation of spiral arteries, endothelial and trophoblast cell activation, and acute atherosis in the basal plate of the placenta. Am J Obstet Gynecol 216 (2017), 287.e1–287.e16.
4. Rich-Edwards, J.W., Ness, R.B., Roberts, J.M., Epidemiology of pregnancy-related hypertension. Taylor, R.N., Roberts, J.M., Cunningham, F.G., Lindheimer, M.D., (eds.) Chesley's hypertensive disorders in pregnancy, 4th Edition, 2015, Elsevier, New York, 37–55.
5. American College of Obstetricians and Gynecologists. Hypertension in pregnancy. 2013, American College of Obstetricians and Gynecologists, Washington (DC), 13–20.
6. Tranquilli, A.L., Dekker, G., Magee, L., et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. Pregnancy Hypertens 4 (2014), 97–104.
7. Sibai, B.M., Preeclampsia as a cause of preterm and late preterm (near-term) births. Semin Perinatol 30 (2006), 16–19.
8. Nelson, D.M., How the placenta affects your life, from womb to tomb. Am J Obstet Gynecol 213:suppl (2015), S12–S13.
9. Brosens, I.A., Robertson, W.B., Dixon, H.G., The role of the spiral arteries in the pathogenesis of pre-eclampsia. J Pathol, 101, 1970 Pvi.
10. Fisher, S.J., Why is placentation abnormal in preeclampsia?. Am J Obstet Gynecol 213:suppl (2015), S115–S122.
11. Kaartokallio, T., Cervera, A., Kyllonen, A., et al. Gene expression profiling of pre-eclamptic placentae by RNA sequencing. Sci Rep, 5, 2015, 14107.
12. Leavey, K., Benton, S.J., Grynspan, D., Kingdom, J.C., Bainbridge, S.A., Cox, B.J., Unsupervised placental gene expression profiling identifies clinically relevant subclasses of human preeclampsia. Hypertension 68 (2016), 137–147.
13. Winn, V.D., Gormley, M., Paquet, A.C., et al. Severe preeclampsia-related changes in gene expression at the maternal-fetal interface include sialic acid-binding immunoglobulin-like lectin-6 and pappalysin-2. Endocrinology 150 (2009), 452–462.
14. Zhou, Y., Gormley, M.J., Hunkapiller, N.M., et al. Reversal of gene dysregulation in cultured cytotrophoblasts reveals possible causes of preeclampsia. J Clin Invest 123 (2013), 2862–2872.
15. American College of Obstetricians and Gynecologists. ACOG practice bulletin, no. 33. Diagnosis and management of preeclampsia and eclampsia. Int J Gynaecol Obstet 77 (2002), 67–75.
16. Herron, M.A., Katz, M., Creasy, R.K., Evaluation of a preterm birth prevention program: preliminary report. Obstet Gynecol 59 (1982), 452–456.
17. Zhou, Y., Bianco, K., Huang, L., et al. Comparative analysis of maternal-fetal interface in preeclampsia and preterm labor. Cell Tissue Res 329 (2007), 559–569.
18. Kim, C.J., Romero, R., Chaemsaithong, P., Kim, J.S., Chronic inflammation of the placenta: definition, classification, pathogenesis, and clinical significance. Am J Obstet Gynecol 213:suppl (2015), S53–S69.
19. Redline, R.W., Classification of placental lesions. Am J Obstet Gynecol 213:suppl (2015), S21–S28.
20. Chu, V.T., Gottardo, R., Raftery, A.E., Bumgarner, R.E., Yeung, K.Y., MeV+R: using MeV as a graphical user interface for bioconductor applications in microarray analysis. Genome Biol, 9, 2008, R118.
21. Ritchie, M.E., Phipson, B., Wu, D., et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res, 43, 2015, e47.
22. Subramanian, A., Tamayo, P., Mootha, V.K., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102 (2005), 15545–15550.
23. Genbacev, O., Larocque, N., Ona, K., et al. Integrin alpha4-positive human trophoblast progenitors: functional characterization and transcriptional regulation. Hum Reprod 31 (2016), 1300–1314.
24. Kliman, H.J., Nestler, J.E., Sermasi, E., Sanger, J.M., Strauss, J.F. 3rd, Purification, characterization, and in vitro differentiation of cytotrophoblasts from human term placentae. Endocrinology 118 (1986), 1567–1582.
25. Fisher, S.J., Cui, T.Y., Zhang, L., et al. Adhesive and degradative properties of human placental cytotrophoblast cells in vitro. J Cell Biol 109 (1989), 891–902.
26. Lee, S., Russo, D., Redman, C., Functional and structural aspects of the Kell blood group system. Transfus Med Rev 14 (2000), 93–103.
27. Zhou, Y., Fisher, S.J., Janatpour, M., et al. Human cytotrophoblasts adopt a vascular phenotype as they differentiate: a strategy for successful endovascular invasion?. J Clin Invest 99 (1997), 2139–2151.
28. Winn, V.D., Haimov-Kochman, R., Paquet, A.C., et al. Gene expression profiling of the human maternal-fetal interface reveals dramatic changes between midgestation and term. Endocrinology 148 (2007), 1059–1079.
29. Redman, C.W., Sargent, I.L., Latest advances in understanding preeclampsia. Science 308 (2005), 1592–1594.
30. Zhou, Y., McMaster, M., Woo, K., et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 160 (2002), 1405–1423.
31. Maynard, S.E., Min, J.Y., Merchan, J., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111 (2003), 649–658.
32. Chen, J.Z., Sheehan, P.M., Brennecke, S.P., Keogh, R.J., Vessel remodelling, pregnancy hormones and extravillous trophoblast function. Mol Cell Endocrinol 349 (2012), 138–144.
33. Simon, T., Gagliano, T., Giamas, G., Direct effects of anti-angiogenic therapies on tumor cells: VEGF signaling. Trends Mol Med 23 (2017), 282–292.
34. Bodnar, L.M., Ness, R.B., Harger, G.F., Roberts, J.M., Inflammation and triglycerides partially mediate the effect of prepregnancy body mass index on the risk of preeclampsia. Am J Epidemiol 162 (2005), 1198–1206.
35. Chaiworapongsa, T., Chaemsaithong, P., Yeo, L., Romero, R., Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol 10 (2014), 466–480.
36. Redman, C.W., Staff, A.C., Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity. Am J Obstet Gynecol 213:suppl (2015), S9.e1–S9.e11.
37. Williamson, R.D., O'Keeffe, G.W., Kenny, L.C., Activin signalling and pre-eclampsia: from genetic risk to pre-symptomatic biomarker. Cytokine 71 (2015), 360–365.
38. DiFederico, E., Genbacev, O., Fisher, S.J., Preeclampsia is associated with widespread apoptosis of placental cytotrophoblasts within the uterine wall. Am J Pathol 155 (1999), 293–301.
39. Acharya, K.R., Ackerman, S.J., Eosinophil granule proteins: form and function. J Biol Chem 289 (2014), 17406–17415.
40. Renaud, S.J., Kubota, K., Rumi, M.A., Soares, M.J., The FOS transcription factor family differentially controls trophoblast migration and invasion. J Biol Chem 289 (2014), 5025–5039.
41. Walton, K.L., Makanji, Y., Harrison, C.A., New insights into the mechanisms of activin action and inhibition. Mol Cell Endocrinol 359 (2012), 2–12.
42. Founds, S.A., Conley, Y.P., Lyons-Weiler, J.F., Jeyabalan, A., Hogge, W.A., Conrad, K.P., Altered global gene expression in first trimester placentas of women destined to develop preeclampsia. Placenta 30 (2009), 15–24.
43. Founds, S.A., Ren, D., Roberts, J.M., Jeyabalan, A., Powers, R.W., Follistatin-like 3 across gestation in preeclampsia and uncomplicated pregnancies among lean and obese women. Reprod Sci 22 (2015), 402–409.
44. Scita, G., Confalonieri, S., Lappalainen, P., Suetsugu, S., IRSp53: crossing the road of membrane and actin dynamics in the formation of membrane protrusions. Trends Cell Biol 18 (2008), 52–60.
45. Belyaeva, O.V., Korkina, O.V., Stetsenko, A.V., Kedishvili, N.Y., Human retinol dehydrogenase 13 (RDH13) is a mitochondrial short-chain dehydrogenase/reductase with a retinaldehyde reductase activity. FEBS J 275 (2008), 138–147.
46. Levine, R.J., Lam, C., Qian, C., et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355 (2006), 992–1005.
47. Wu, P., van den Berg, C., Alfirevic, Z., et al. Early pregnancy biomarkers in pre-eclampsia: a systematic review and meta-analysis. Int J Mol Sci 16 (2015), 23035–23056.
48. Vahakangas, K., Myllynen, P., Drug transporters in the human blood-placental barrier. Br J Pharmacol 158 (2009), 665–678.
49. Shimizu, H., Watanabe, E., Hiyama, T.Y., et al. Glial Nax channels control lactate signaling to neurons for brain [Na+] sensing. Neuron 54 (2007), 59–72.
50. Lee, T.W., Tsang, V.W., Loef, E.J., Birch, N.P., Physiological and pathological functions of neuroserpin: regulation of cellular responses through multiple mechanisms. Semin Cell Dev Biol 62 (2017), 152–159.
51. Martinez, A.I., Perez-Arellano, I., Pekkala, S., Barcelona, B., Cervera, J., Genetic, structural and biochemical basis of carbamoyl phosphate synthetase 1 deficiency. Mol Genet Metab 101 (2010), 311–323.
52. Moonen, R.M., Cavallaro, G., Huizing, M.J., Gonzalez-Luis, G.E., Mosca, F., Villamor, E., Association between the p.Thr1406Asn polymorphism of the carbamoyl-phosphate synthetase 1 gene and necrotizing enterocolitis: a prospective multicenter study. Sci Rep, 6, 2016, 36999.
53. Fujigaki, H., Yamamoto, Y., Saito, K., L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: focus on cell type differences. Neuropharmacology 112 (2017), 264–274.
54. Munn, D.H., Zhou, M., Attwood, J.T., et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281 (1998), 1191–1193.
55. Johansson, A.S., Mannervik, B., Human glutathione transferase A3-3, a highly efficient catalyst of double-bond isomerization in the biosynthetic pathway of steroid hormones. J Biol Chem 276 (2001), 33061–33065.
56. Zheng, R., Heck, D.E., Black, A.T., Gow, A., Laskin, D.L., Laskin, J.D., Regulation of keratinocyte expression of stress proteins and antioxidants by the electrophilic nitrofatty acids 9- and 10-nitrooleic acid. Free Radic Biol Med 67 (2014), 1–9.
57. Vargas, A., Toufaily, C., LeBellego, F., Rassart, E., Lafond, J., Barbeau, B., Reduced expression of both syncytin 1 and syncytin 2 correlates with severity of preeclampsia. Reprod Sci 18 (2011), 1085–1091.
58. Zalewska, M., Trefon, J., Milnerowicz, H., The role of metallothionein interactions with other proteins. Proteomics 14 (2014), 1343–1356.
59. Liu, Q., Li, A., Tian, Y., et al. The CXCL8-CXCR1/2 pathways in cancer. Cytokine Growth Factor Rev 31 (2016), 61–71.
60. Levinson, B., Kenwrick, S., Lakich, D., Hammonds, G. Jr., Gitschier, J., A transcribed gene in an intron of the human factor VIII gene. Genomics 7 (1990), 1–11.
61. Ayer, A., Zarjou, A., Agarwal, A., Stocker, R., Heme oxygenases in cardiovascular health and disease. Physiol Rev 96 (2016), 1449–1508.
62. Zhao, H., Wong, R.J., Kalish, F.S., Nayak, N.R., Stevenson, D.K., Effect of heme oxygenase-1 deficiency on placental development. Placenta 30 (2009), 861–868.
63. DeWire, S.M., Violin, J.D., Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology. Circ Res 109 (2011), 205–216.
64. Red-Horse, K., Kapidzic, M., Zhou, Y., Feng, K.T., Singh, H., Fisher, S.J., EPHB4 regulates chemokine-evoked trophoblast responses: a mechanism for incorporating the human placenta into the maternal circulation. Development 132 (2005), 4097–4106.
65. Zhang, S., Hulver, M.W., McMillan, R.P., Cline, M.A., Gilbert, E.R., The pivotal role of pyruvate dehydrogenase kinases in metabolic flexibility. Nutr Metab (Lond), 11, 2014, 10.
66. Sato-Nishiuchi, R., Nakano, I., Ozawa, A., et al. Polydom/SVEP1 is a ligand for integrin alpha9beta1. J Biol Chem 287 (2012), 25615–25630.
67. Myocardial Infarction Genetics Investigators CARDIoGRAM Exome Consortium Investigators. Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease. N Engl J Med 374 (2016), 1134–1144.
68. Nakada, T.A., Russell, J.A., Boyd, J.H., Thair, S.A., Walley, K.R., Identification of a nonsynonymous polymorphism in the SVEP1 gene associated with altered clinical outcomes in septic shock. Crit Care Med 43 (2015), 101–108.
69. Fong, F.M., Sahemey, M.K., Hamedi, G., et al. Maternal genotype and severe preeclampsia: a HuGE review. Am J Epidemiol 180 (2014), 335–345.
70. Hunkapiller, N.M., Gasperowicz, M., Kapidzic, M., et al. A role for Notch signaling in trophoblast endovascular invasion and in the pathogenesis of pre-eclampsia. Development 138 (2011), 2987–2998.
71. Than, N.G., Romero, R., Goodman, M., et al. A primate subfamily of galectins expressed at the maternal-fetal interface that promote immune cell death. Proc Natl Acad Sci U S A 106 (2009), 9731–9736.
72. Than, N.G., Romero, R., Xu, Y., et al. Evolutionary origins of the placental expression of chromosome 19 cluster galectins and their complex dysregulation in preeclampsia. Placenta 35 (2014), 855–865.
73. Blois, S.M., Dechend, R., Barrientos, G., Staff, A.C., A potential pathophysiological role for galectins and the renin-angiotensin system in preeclampsia. Cell Mol Life Sci 72 (2015), 39–50.
74. Kzhyshkowska, J., Yin, S., Liu, T., Riabov, V., Mitrofanova, I., Role of chitinase-like proteins in cancer. Biol Chem 397 (2016), 231–247.
75. Kong, L., Hao, Q., Wang, Y., Zhou, P., Zou, B., Zhang, Y.X., Regulation of p53 expression and apoptosis by vault RNA2-1-5p in cervical cancer cells. Oncotarget 6 (2015), 28371–28388.
76. Li, W., Tailhades, J., O'Brien-Simpson, N.M., et al. Proline-rich antimicrobial peptides: potential therapeutics against antibiotic-resistant bacteria. Amino Acids 46 (2014), 2287–2294.
77. Khalili, H., Sull, A., Sarin, S., et al. Developmental origins for kidney disease due to shroom3 deficiency. J Am Soc Nephrol 27 (2016), 2965–2973.
78. Capurro, M., Martin, T., Shi, W., Filmus, J., Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling. J Cell Sci 127 (2014), 1565–1575.
79. Peeters, M.C., Fokkelman, M., Boogaard, B., et al. The adhesion G protein-coupled receptor G2 (ADGRG2/GPR64) constitutively activates SRE and NFkappaB and is involved in cell adhesion and migration. Cell Signal 27 (2015), 2579–2588.
80. O'Shea, N.R., Chew, T.S., Dunne, J., et al. Critical role of the disintegrin metalloprotease ADAM-like Decysin-1 [ADAMDEC1] for intestinal immunity and inflammation. J Crohns Colitis 10 (2016), 1417–1427.
81. Wilson, G.J., Hewit, K.D., Pallas, K.J., et al. Atypical chemokine receptor ACKR2 controls branching morphogenesis in the developing mammary gland. Development 144 (2017), 74–82.
82. Xue, M., Chen, W., Li, X., Urothelial cancer associated 1: a long noncoding RNA with a crucial role in cancer. J Cancer Res Clin Oncol 142 (2016), 1407–1419.
83. Meier, U.T., RNA modification in Cajal bodies. RNA Biol, 2016, 1–8.
84. Machyna, M., Neugebauer, K.M., Stanek, D., Coilin: The first 25 years. RNA Biol 12 (2015), 590–596.
85. De Groot, C.J., Steegers-Theunissen, R.P., Guzel, C., Steegers, E.A., Luider, T.M., Peptide patterns of laser dissected human trophoblasts analyzed by matrix-assisted laser desorption/ionisation-time of flight mass spectrometry. Proteomics 5 (2005), 597–607.
86. Guller, S., Ma, Y.Y., Fu, H.H., Krikun, G., Abrahams, V.M., Mor, G., The placental syncytium and the pathophysiology of preeclampsia and intrauterine growth restriction: a novel assay to assess syncytial protein expression. Ann N Y Acad Sci 1127 (2008), 129–133.
87. Guzel, C., Ursem, N.T., Dekker, L.J., et al. Multiple reaction monitoring assay for pre-eclampsia related calcyclin peptides in formalin fixed paraffin embedded placenta. J Proteome Res 10 (2011), 3274–3282.
88. Ma, K., Jin, H., Hu, R., et al. A proteomic analysis of placental trophoblastic cells in preeclampsia-eclampsia. Cell Biochem Biophys 69 (2014), 247–258.
89. Richani, K., Romero, R., Soto, E., et al. Genetic origin and proportion of basal plate surface-lining cells in normal and abnormal pregnancies. Hum Pathol 38 (2007), 269–275.
90. He, P., Shao, D., Ye, M., Zhang, G., Analysis of gene expression identifies candidate markers and pathways in pre-eclampsia. J Obstet Gynaecol 35 (2015), 578–584.
91. Pihl, K., Larsen, T., Rasmussen, S., Krebs, L., Christiansen, M., The proform of eosinophil major basic protein: a new maternal serum marker for adverse pregnancy outcome. Prenat Diagn 29 (2009), 1013–1019.
92. Soragni, A., Yousefi, S., Stoeckle, C., et al. Toxicity of eosinophil MBP is repressed by intracellular crystallization and promoted by extracellular aggregation. Mol Cell 57 (2015), 1011–1021.
93. Weyer, K., Glerup, S., Placental regulation of peptide hormone and growth factor activity by proMBP. Biol Reprod 84 (2011), 1077–1086.
94. Lopez-Bergami, P., Lau, E., Ronai, Z., Emerging roles of ATF2 and the dynamic AP1 network in cancer. Nat Rev Cancer 10 (2010), 65–76.
95. Eferl, R., Sibilia, M., Hilberg, F., et al. Functions of c-Jun in liver and heart development. J Cell Biol 145 (1999), 1049–1061.
96. Schorpp-Kistner, M., Wang, Z.Q., Angel, P., Wagner, E.F., JunB is essential for mammalian placentation. EMBO J 18 (1999), 934–948.
97. Denomme, G.A., Kell and Kx blood group systems. Immunohematology 31 (2015), 14–19.
98. Badjie, K.S., Tauscher, C.D., van Buskirk, C.M., et al. Red blood cell phenotype matching for various ethnic groups. Immunohematology 27 (2011), 12–19.
99. Moise, K.J., Fetal anemia due to non-Rhesus-D red-cell alloimmunization. Semin Fetal Neonatal Med 13 (2008), 207–214.
100. Vaughan, J.I., Manning, M., Warwick, R.M., Letsky, E.A., Murray, N.A., Roberts, I.A., Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmune anemia. N Engl J Med 338 (1998), 798–803.
101. Claperon, A., Rose, C., Gane, P., Collec, E., Bertrand, O., Ouimet, T., The Kell protein of the common K2 phenotype is a catalytically active metalloprotease, whereas the rare Kell K1 antigen is inactive: identification of novel substrates for the Kell protein. J Biol Chem 280 (2005), 21272–21283.
102. Khalil, R.A., Granger, J.P., Vascular mechanisms of increased arterial pressure in preeclampsia: lessons from animal models. Am J Physiol Regul Integr Comp Physiol 283 (2002), R29–R45.
103. Zhou, Y., Damsky, C.H., Fisher, S.J., Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome?. J Clin Invest 99 (1997), 2152–2164.
104. Morris, B.J., Renin, genes, microRNAs, and renal mechanisms involved in hypertension. Hypertension 65 (2015), 956–962.
105. Brown, J.J., Davies, D.L., Doak, P.B., Lever, A.F., Robertson, J.I., Trust, P., Plasma-renin concentration in hypertensive disease of pregnancy. Lancet, 2, 1965, 1219.
106. Brown, J.J., Davies, D.L., Doak, P.B., Lever, A.F., Robertson, J.I., Trust, P., Plasma renin concentration in the hypertensive diseases of pregnancy. J Obstet Gynaecol Br Commonw 73 (1966), 410–417.
107. Chesley, L.C., Vascular reactivity in normal and toxemic pregnancy. Clin Obstet Gynecol 9 (1966), 871–881.
108. Talledo, O.E., O: renin-angiotensin system in normal and toxemic pregnancies. IV. Inactivation of angiotensin in toxemic pregnancy. Am J Obstet Gynecol 101 (1968), 254–256.
109. Gant, N.F., Daley, G.L., Chand, S., Whalley, P.J., MacDonald, P.C., A study of angiotensin II pressor response throughout primigravid pregnancy. J Clin Invest 52 (1973), 2682–2689.
110. Herse, F., Dechend, R., Harsem, N.K., et al. Dysregulation of the circulating and tissue-based renin-angiotensin system in preeclampsia. Hypertension 49 (2007), 604–611.
111. Pineles, B.L., Romero, R., Montenegro, D., et al. Distinct subsets of microRNAs are expressed differentially in the human placentas of patients with preeclampsia. Am J Obstet Gynecol 196 (2007), 261.e1–261.e6.
112. Morales-Prieto, D.M., Ospina-Prieto, S., Schmidt, A., Chaiwangyen, W., Markert, U.R., Elsevier Trophoblast Research Award Lecture: origin, evolution and future of placenta miRNAs. Placenta 35:suppl (2014), S39–S45.
113. Cox, B., Leavey, K., Nosi, U., Wong, F., Kingdom, J., Placental transcriptome in development and pathology: expression, function, and methods of analysis. Am J Obstet Gynecol 213:suppl (2015), S138–S151.
114. Mouillet, J.F., Ouyang, Y., Coyne, C.B., Sadovsky, Y., MicroRNAs in placental health and disease. Am J Obstet Gynecol 213:suppl (2015), S163–S172.
115. Wilusz, J.E., Long noncoding RNAs: Re-writing dogmas of RNA processing and stability. Biochim Biophys Acta 1859 (2016), 128–138.
116. Venteicher, A.S., Abreu, E.B., Meng, Z., et al. A human telomerase holoenzyme protein required for Cajal body localization and telomere synthesis. Science 323 (2009), 644–648.
117. Lemm, I., Girard, C., Kuhn, A.N., et al. Ongoing U snRNP biogenesis is required for the integrity of Cajal bodies. Mol Biol Cell 17 (2006), 3221–3231.
118. Velma, V., Broome, H.J., Hebert, M.D., Regulated specific proteolysis of the Cajal body marker protein coilin. Chromosoma 121 (2012), 629–642.
119. Januar, V., Desoye, G., Novakovic, B., Cvitic, S., Saffery, R., Epigenetic regulation of human placental function and pregnancy outcome: considerations for causal inference. Am J Obstet Gynecol 213:suppl (2015), S182–S196.